Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9(+) tumors

Relapsed or refractory T acute lymphoblastic leukemia (T-ALL) still carries poor prognosis. Aiming to improve outcomes, the therapeutic potential of an anti-CCR9 monoclonal antibody (mAb 92R), targeting the human chemokine-receptor CCR9 is analyzed on orthotopic xenotransplants. 92R mAb treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Santamaria, Silvia, Delgado, Marisa, Botas, Marta, Castellano, Eva, Corraliza-Gorjon, Isabel, Lafuente, Paloma, Muñoz-Calleja, Cecilia, Toribio, Maria L., Kremer, Leonor, Garcia-Sanz, Jose A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363564/
https://www.ncbi.nlm.nih.gov/pubmed/35967322
http://dx.doi.org/10.3389/fimmu.2022.825635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363564/
https://www.ncbi.nlm.nih.gov/pubmed/35967322
http://dx.doi.org/10.3389/fimmu.2022.825635

Ejemplares similares